rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Altimmune, Inc. (ALT) Presents at American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2026 - Slideshow

      2026-11-14. The following slide deck was published by Altimmune, Inc.

      Nov 14Seeking AlphaALT
      Altimmune director Wayne Pisano buys $16,350 in company stock
      Nov 14Investing.comALT
      ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
      Nov 13Yahoo FinanceALT
      Citizens reiterates Altimmune stock rating on expanding pemvidutide data
      Nov 13Investing.comALT
      Altimmune: Still Too Late And Too Capital-Intensive

      Altimmune remains a Sell as pemvidutide lacks clear differentiation in the competitive MASH landscape. Read more on ALT stock here.

      Nov 12Seeking AlphaALT
      Altimmune, Inc. Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceALT
      What Altimmune (ALT) Said on Its Q3 Earnings Call
      Nov 12Yahoo FinanceALT
      Altimmune Q3 2026 Earnings Call Transcript
      Nov 12BenzingaALT
      Altimmune Announces Third Quarter 2026 Financial Results and Business Update
      Nov 12Yahoo FinanceALT
      Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
      Nov 9Yahoo FinanceALT
      Altimmune to present alcohol use disorder trial data Monday
      Nov 5Investing.comALT
      Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
      Nov 5Yahoo FinanceALT
      Altimmune adds two directors as three board members plan exit
      Oct 27Investing.comALT
      Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
      Oct 27Yahoo FinanceALT
      Altimmune to present pemvidutide liver disease data at AASLD
      Oct 19Investing.comALT
      Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
      Oct 19Yahoo FinanceALT
      Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)

      Tipranks Press Release.

      Oct 10The Globe and MailALT
      Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise

      Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or AL

      Oct 1Yahoo FinanceALT
      Altimmune at Stifel 2026 Virtual Cardiometabolic Forum: liver push
      Sep 30Investing.comALT
      Altimmune Appoints Richard Menziuso as Principal Accounting Officer

      Detailed price information for Altimmune Inc (ALT-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailALT
      Altimmune appoints Richard Menziuso as vice president and principal accounting officer
      Sep 29Investing.comALT
      Altimmune to Participate in Stifel Cardiometabolic Forum

      GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic

      Sep 23Yahoo FinanceALTSF
      VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
      Sep 21Yahoo FinanceALTNVO
      Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

      Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 11Yahoo FinanceALT
      Altimmune at Wells Fargo healthcare conference: pemvidutide push
      Sep 10Investing.comALTWFC
      Altimmune’s (ALT) Three Liver Trials Move Forward At Once
      Sep 8Yahoo FinanceALT
      Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

      GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clin

      Sep 3Yahoo FinanceALT

      This is the newest page. Registered accounts read further back.